Previous 10 | Next 10 |
Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patients Showed No Decline And 60% Showed Clinical Improvement At 18 Months in Low-Tau Subpopulation in Additional Analysis of Clarity AD ...
2023-10-25 13:59:34 ET More on Cassava Sciences Cassava Sciences' Integrity Under Scrutiny Following CUNY Misconduct Claims Cassava Sciences: Update Following Leaked CUNY Report, Fundamentals Remain Unchanged Cassava Sciences: Unconvincing Open Label Studies, Upcomin...
2023-10-25 12:00:42 ET More on Biogen, Ionis, etc. Biogen - Revised Revenue Forecasting To 2030 - New CEO Faces Major Challenges Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript) Biogen Inc. (BIIB) Morgan Stanley...
In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and function. First study of a tau targeting drug that shows reduction of aggregated tau pathology and favorable trends on clinical outcomes. Recruitment is underway for the ...
LEQEMBI® (lecanemab-irmb) NAMED ONE OF TIME's BEST INVENTIONS OF 2023 PR Newswire Recognized in the Medical Care Category NUTLEY, N.J. , and CAMBRIDGE, Mass. , Oct. 24, 2023 /PRNewswire/ -- Eisai Inc. and Biogen Inc. are honored to annou...
Late-breaking Phase 1b data assesses the clinical outcomes of reducing tau in patients with early-stage Alzheimer’s disease Additional late-breaking presentations from the CLARITY AD study explore predictive biomarkers and novel subcutaneous administration of LEQEMBI ® (lecane...
2023-10-18 18:52:03 ET Summary Sage Therapeutics, Inc. received FDA approval along with Biogen for its drug ZURZUVAE for the treatment of postpartum depression, with a planned launch in Q4 2023. The company has several ongoing studies using its drug SAGE-718 for the treatment of H...
2023-10-18 12:49:03 ET Summary Incyte's stock has declined nearly 60% from all-time highs in 2017 due to market volatility, regulatory challenges, and increased competition. Despite the decline, Incyte reported strong financial performance with a 25% increase in net product revenu...
2023-10-18 08:23:00 ET Stocks that are crashing in value can sometimes make for good contrarian investments -- provided that there's a reason to expect a turnaround. But in some situations, investors are better off just avoiding businesses that are in trouble and whose valuations may only e...
2023-10-18 03:30:00 ET Summary ClearBridge All Cap Value Strategy invests in a diversified portfolio of stocks whose prices are undervalued in relation to underlying fundamentals. The transition to a higher rate environment has increased risks and concerns over companies accustome...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...